The KDM5B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa cell line, engineered to disrupt the KDM5B gene. This product provides a loss-of-function model for the histone demethylase KDM5B, enabling studies of its role in epigenetic regulation and cancer biology. The polyclonal format captures a heterogeneous spectrum of editing events, offering a practical system for assessing gene function without single-cell cloning. These cells serve as a versatile tool for functional genomics, drug discovery, and mechanistic investigations into KDM5B-dependent processes.
HeLa cells, isolated from a human cervical adenocarcinoma, are an aneuploid, HPV18-positive epithelial cell line with robust proliferation and transfectability. As one of the most widely used immortalized cell lines, HeLa cells provide a consistent and well-characterized model for cancer research. Their ease of genetic manipulation makes them an ideal host for CRISPR-mediated gene disruption studies. The HeLa background allows the exploration of KDM5B function in a cancer-relevant context, where epigenetic dysregulation is a hallmark of malignancy, offering insights into tumor biology and therapeutic vulnerabilities.
KDM5B encodes a JmjC-domain-containing histone demethylase that specifically removes di- and trimethyl groups from lysine 4 of histone H3 (H3K4me2/3), serving as a transcriptional repressor. Its activity is modulated by upstream regulators including OCT4, SOX2, NANOG, Notch intracellular domain, TGF-??, and HIF1??. KDM5B demethylation of nucleosomes near gene promoters leads to the silencing of downstream targets such as CDKN1A (p21), HOXA genes, and CDH1, thereby promoting proliferation and inhibiting differentiation. It interacts with repressive complexes like PRC2 (via EZH2), HDAC1/2, SIN3A, Rb, and the CoREST complex, reinforcing chromatin compaction and heritable gene silencing.
In the context of HeLa cervical carcinoma cells, KDM5B knockout disrupts the epigenetic silencing of tumor suppressor genes, potentially restoring expression of cell cycle inhibitors and differentiation markers. This model recapitulates aspects of KDM5B-driven oncogenesis, including the maintenance of a stem-like phenotype and uncontrolled cell division. By ablating KDM5B, researchers can dissect its contribution to Notch and TGF-?? signaling pathways, and investigate its interplay with PRC2 and HDAC-mediated repression. Consequently, this cellular system is valuable for validating KDM5B as a therapeutic target and studying resistance mechanisms in cancers with aberrant histone demethylation.
Typical applications include chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to measure H3K4me3 enrichment at target gene promoters, transcriptome profiling via RNA-seq, and quantitative real-time PCR (RT-qPCR) for downstream targets like p21 and HOXA. Protein-level validation can be performed by Western blotting for KDM5B and histone marks, while immunofluorescence allows subcellular localization studies. Functional assays such as MTT and colony formation enable assessment of proliferation and clonogenic capacity. This polyclonal knockout population is also suited for high-throughput screens to identify KDM5B inhibitors and for investigating epigenetic combination therapies. For further technical information and lot-specific details, please contact Ascent Research.
